Pfizer helps pump $103M into startup to develop new cancer therapies

A New York startup has been spun-out of Pfizer to develop clinical-stage experimental therapies. Nascent medicine company SpringWorks Therapeutics completed a $103 million series A round led by the New York-based pharma giant with the help of Bain Capital, OrbiMed and LifeArc (formerly known as MRC Technology). Pfizer (NYSE: PFE) granted SpringWorks the rights to help develop four drugs or t herapies that treat various conditions, including post-traumatic stress disorder and cancer. Another New…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news